Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its nano-engineered platform technology and its product PRV111 for oral cancer at two major events in Asia. In January 2019, Privo...
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR Bridge Award supports Privo's clinical trial for its nanotechnology-based treatment of oral cancer. This award was given to only 4 companies...
BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to begin patient recruitment for a prospective clinical trial (NCT03502148) targeting early-stage oral cavity squamous cell carcinoma (OCSCC). Privo is now actively...
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work...
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated in the top 5% of all award applicants. Go to article
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and would like to thank the National Cancer Institute for funding Privo’s inclusion as part of this conference.
Privo a $2.5M grant to optimize it lead product and prepare for its IND.
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place, Suite 6B in Peabody, Massachusetts, the new facility consists of two separate research labs that will be used in its...
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral cancer treatments to additional patent protection, 7 years of drug exclusivity, and tax credits equal to 50% of research and...
- © UX Strategy & Digital Branding